May Daher, MD

Peer-Reviewed Articles

1. Biederstadt A, Basar R, Park JM, Uprety N, Shrestha R, Reyes Silva F, Dede M, Watts J, Acharya S, Xiong D, Liu B, Daher M, Rafei H, Banerjee P, Li P, Islam S, Fan H, Shanley M, Jin J, Kumar B, Woods V, Lin P, Tiberti S, Nunez Cortes AK, Jiang XR, Biederstadt I, Zhang P, Li Y, Rawal S, Liu E, Muniz-Feliciano L, Deyter GM, Shpall EJ, Fowlkes NW, Chen K, Rezvani K. Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer Cell, 2025. e-Pub 2025. PMID: 40845844.
2. Daher M, Rezvani K. iPSC-derived CAR-NK cells: Off-the-shelf cellular therapy for systemic sclerosis. Cell 188(16):4173-4174, 2025. e-Pub 2025. PMID: 40780183.
3. Rafei H, Basar R, Acharya S, Hsu YS, Liu P, Zhang D, Bohn T, Liang Q, Mohanty V, Upadhyay R, Li P, Phadatare P, Dede M, Xiong D, Fan H, Jones CM, Kunz S, Daher M, Nunez Cortes AK, Shanley M, Liu B, Moseley SM, Zhang C, Fang D, Banerjee P, Uprety N, Li Y, Shrestha R, Wan X, Shen H, Woods V, Gilbert AL, Rawal S, Dou J, Tan Y, Park JM, Reyes Silva F, Biederstadt A, Kaplan M, Jiang XR, Biederstadt I, Kumar B, Tiberti S, Moore M, Jin J, Yang RZ, Muniz-Feliciano L, Rosemore S, Lin P, Deyter GM, Fowlkes NW, Jain AK, Marin D, Maitra A, Chen K, Bopp T, Shpall EJ, Rezvani K. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643(8073):1076-1086, 2025. e-Pub 2025. PMID: 40468083.
4. Rodriguez-Sevilla, JJ, Ganan Gomez, I, Kumar, B, Thongon, N, Ma, F, Chien, KS, Kim, YJ, Yang, H, Loghavi, S, Tan, R, Ademà Llobet, V, Li, Z, Tanaka, T, Uryu, H, Kanagal Shamanna, R, Al-Atrash, G, Bejar, R, Banerjee, PP, Lynn Cha, S, Montalban Bravo, G, Dougherty, M, Fernandez Laurita, MC, Wheeler, N, Jia, B, Papapetrou, EP, Izzo, F, Duenas, DE, McAllen, S, Gu, Y, Todisco, G, Ficara, F, Della Porta, M, Jain, A, Takahashi, K, Dwyer, KC, Halene, S, Bertilaccio, MS, Garcia-Manero, G, Daher, M, Colla, S. Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40216768.
5. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
6. Manzar, G, Wu, SY, Dudzinski, SO, Cha, E, Yoder, A, Corrigan, KL, Nasr, L, Sallard, G, Ahmed, S, Fayad, LE, Chihara, D, Nair, R, Westin, JR, Daher, M, Neelapu, SS, Nastoupil, L, Gunther, J, Pinnix, CC, Dabaja, BS, Strati, P, Fang, PQ. Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy. International Journal of Radiation Oncology Biology Physics 121(4):1011-1025, 2025. e-Pub 2025. PMID: 39303997.
7. Wang Y, Casarin S, Daher M, Mohanty V, Dede M, Shanley M, Basar R, Rezvani K, Chen K. Agent-based modeling of cellular dynamics in adoptive cell therapy. bioRxiv, 2025. e-Pub 2025. PMID: 40027823.
8. Melo Garcia, L, Gangadharan, A, Banerjee, PP, Li, YE, Zeng, A, Rafei, H, Lin, P, Kumar, B, Acharya, S, Daher, M, Muniz-Feliciano, L, Deyter, GM, Dominguez, G, Park, JM, Reyes Silva, F, Nunez Cortes, AK, Basar, R, Uprety, N, Shanley, M, Kaplan, M, Liu, E, Shpall, E, Rezvani, K. Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell Reports 44(1), 2025. e-Pub 2025. PMID: 39754720.
9. Yeh, JC, Pasvolsky, O, Saliba, RM, Figgins, B, Wang, C, Fang, Z, Ahmed, S, Yilmaz, M, Daver, N, Ravandi, F, DiNardo, CD, Short, NJ, Kadia, TM, Al-Atrash, G, Daher, M, Costa, DM, Popat, U, Champlin, R, Shpall, EJ, Oran, B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
10. Marques-Piubelli, ML, Kumar, B, Basar, R, Panowski, S, Srinivasan, S, Norwood, K, Prashad, SL, Szenes, V, Balakumaran, A, Arandhya, A, Lu, W, Khan, KB, Duenas, D, McAllen, S, Gomez, JA, Burks, JK, Acharyal, S, Borthakur, G, Wang, WL, Wang, W, Wang, S, Solis Soto, LM, Marin, D, Rezvani, K, Daher, M, Vega Vazquez, F. Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Archiv 485(5):937-941, 2024. e-Pub 2024. PMID: 38388965.
11. Acharya, S, Basar, R, Daher, M, Rafei, H, Li, P, Uprety, N, Ensley, E, Shanley, M, Kumar, B, Banerjee, PP, Melo Garcia, L, Lin, P, Mohanty, V, Kim, KH, Jiang, XL, Pan, Y, Li, YE, Liu, B, Nunez Cortes, Ak, Zhang, C, Fathi, M, Rezvan, A, Montalvo, MJ, Cha, SL, Reyes Silva, F, Shrestha, R, Guo, X, Kundu, K, Biederstädt, A, Muniz-Feliciano, L, Deyter, GM, Kaplan, M, Jiang, XR, Liu, E, Jain, A, Roszik, J, Fowlkes, NW, Solis Soto, LM, Raso, G, Khoury, J, Lin, P, Vega Vazquez, F, Varadarajan, N, Chen, K, Marin, D, Shpall, E, Rezvani, K. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ ZAP70 Signaling Axis. Cancer discovery 14(10):1879-1900, 2024. e-Pub 2024. PMID: 38900051.
12. Kumar, B, Singh, A, Basar, R, Uprety, N, Li, YE, Fan, H, Nunez Cortes, Ak, Kaplan, M, Acharya, S, Shaim, H, Xu, AC, Wu, M, Ensley, E, Fang, D, Banerjee, PP, Melo Garcia, L, Tiberti, S, Lin, P, Rafei, H, Munir, MN, Moore, M, Shanley, M, Mendt Vilchez, MC, Kerbauy, LN, Liu, B, Biederstädt, A, Gokdemir, E, Ghosh, S, Kundu, K, Reyes Silva, F, Jiang, XR, Wan, X, Gilbert, AL, Dede, M, Mohanty, V, Dou, J, Zhang, P, Liu, E, Muniz-Feliciano, L, Deyter, GM, Jain, A, Rodriguez-Sevilla, JJ, Colla, S, Garcia-Manero, G, Shpall, E, Chen, K, Abbas, HA, Rai, K, Rezvani, K, Daher, M. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Science translational medicine 16(764), 2024. e-Pub 2024. PMID: 39259809.
13. Shanley, M, Daher, M, Dou, J, Li, S, Basar, R, Rafei, H, Dede, M, Gumin, J, Pantaleόn Garcίa, J, Nunez Cortes, AK, He, S, Jones, C, Acharya, S, Fowlkes, NW, Xiong, D, Singh, S, Shaim, H, Hicks, SC, Liu, B, Jain, A, Zaman, MF, Miao, Q, Li, YE, Uprety, N, Liu, E, Muniz-Feliciano, L, Deyter, GM, Mohanty, V, Zhang, P, Evans, S, Shpall, EJ, Lang Jr, FF, Chen, K, Rezvani, K. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell 42(8):1450-1466.e11, 2024. e-Pub 2024. PMID: 39137729.
14. Febres-Aldana, A, Khawaja, F, Morado-Aramburo, O, Shigle, TL, Rondon, G, Sassine, J, Spallone, A, Srinivasan, K, Ramdial, JL, Alousi, AM, Champlin, RE, Chen, GL, Daher, M, Rezvani, K, Ariza Heredia, E, Shpall, E, Chemaly, RF. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis. Clinical Microbiology and Infection 30(6):803-809, 2024. e-Pub 2024. PMID: 38460821.
15. Khouri, IF, Alzahrani, K, Kantarjian, HM, Milton, D, Gulbis, A, Sasaki, K, Jain, N, Short, NJ, Kadia, TM, Daher, M, Rafei, H, Im, JS, Marin, D, Olson, AL, Popat, UR, Qazilbash, MH, Ramdial, JL, Rondon, G, Srour, S, Kebriaei, P, Shpall, E, Champlin, RE, Jabbour, EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
16. Marin, D, Li, Y, Basar, R, Rafei, H, Daher, M, Dou, J, Mohanty, V, Dede, M, Nieto, Y, Uprety, N, Acharya, S, Liu, E, Wilson, JM, Banerjee, PP, Macapinlac, HA, Ganesh, C, Thall, PF, Bassett Jr, R, Ammari, M, Rao, SS, Cao, K, Shanley, M, Kaplan, M, Hosing, C, Kebriaei, P, Nastoupil, L, Flowers, CR, Moseley, SM, Lin, P, Ang, O, Popat, UR, Qazilbash, MH, Champlin, RE, Chen, K, Shpall, E, Rezvani, K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors. Nature medicine 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
17. Nieto, Y, Banerjee, PP, Kaur, I, Kim, KH, Fang, D, Thall, PF, Griffin, L, Barnett, M, Basar, R, Hosing, C, Ramdial, JL, Srour, S, Daher, M, Marin, D, Jiang, X, Chen, K, Champlin, RE, Shpall, E, Rezvani, K. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy 30(2):203.e1-203.e9, 2024. e-Pub 2024. PMID: 38042257.
18. Mohanty V, Baran N, Huang Y, Ramage CL, Cooper LM, He S, Iqbal R, Daher M, Tyner JW, Mills GB, Konopleva M, Chen K. Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. bioRxiv, 2024. e-Pub 2024. PMID: 38352538.
19. Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RF. Hematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant 58(12):1410-1412, 2023. e-Pub 2023. PMID: 37726490.
20. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
21. Huang Y, Mohanty V, Dede M, Tsai K, Daher M, Li L, Rezvani K, Chen K. Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nat Commun 14(1):4883, 2023. e-Pub 2023. PMID: 37573313.
22. Li, L, Mohanty, V, Dou, J, Huang, Y, Banerjee, PP, Miao, Q, Lohr, JG, Vijaykumar, T, Frede, J, Knoechel, B, Muniz-Feliciano, L, Laskowski, TJ, Liang, S, Moyes, JS, Nandivada, V, Basar, R, Kaplan, M, Daher, M, Liu, E, Li, Y, Acharya, S, Lin, P, Shanley, M, Rafei, H, Marin, D, Mielke, S, Champlin, RE, Shpall, E, Chen, K, Rezvani, K. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Science Advances 9(30), 2023. e-Pub 2023. PMID: 37494448.
23. Faak, F, Buni, M, Falohun, A, Lu, H, Song, J, Johnson, DH, Zobniw, C, Trinh, VA, Awiwi, M, Tahon, NH, Elsayes, KM, Ludford, K, Montazari, EJ, Chernis, J, Dimitrova, M, Sandigursky, S, Sparks, JA, Abu-Shawer, O, Rahma, OE, Thanarajasingam, U, Zeman, AM, Talukder, R, Singh, N, Chung, SH, Grivas, PD, Daher, M, Abudayyeh, A, Osman, I, Weber, JS, Tayar, JH, Suarez-Almazor, M, Hassan, NA, Diab, A. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. Journal for immunotherapy of cancer 11(6), 2023. e-Pub 2023. PMID: 37328287.
24. Lui A, Lee J, Thall PF, Daher M, Rezvani K, Basar R. A Bayesian feature allocation model for identifying cell subpopulations using CyTOF data. J R Stat Soc Ser C Appl Stat 72(3):718-738, 2023. e-Pub 2023. PMID: 37325776.
25. Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, Olson A. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med 12(2):55-71, 2023. e-Pub 2023. PMID: 36779789.
26. Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, FLWI L, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer 10(12), 2022. e-Pub 2022. PMID: 36543374.
27. Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstädt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med 28(10):2133-2144, 2022. e-Pub 2022. PMID: 36175679.
28. Kumar, B, Afshar-Kharghan, V, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Popat, UR, Ramdial, JL, Daher, M, Jimenez, J, Basar, R, Melo Garcia, L, Shanley, M, Kaplan, M, Wan, X, Nandivada, V, Reyes Silva, F, Woods, V, Gilbert, AL, Gonzalez-Delgado, R, Acharya, S, Lin, P, Rafei, H, Banerjee, PP, Shpall, E. Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 36203567.
29. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
30. Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun 13(1):2801, 2022. e-Pub 2022. PMID: 35589701.
31. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
32. Dou J, Liang S, Mohanty V, Miao Q, Huang Y, Liang Q, Cheng X, Kim S, Choi J, Li Y, Li L, Daher M, Basar R, Rezvani K, Chen R, Chen K. Bi-order multimodal integration of single-cell data. Genome Biol 23(1):112, 2022. e-Pub 2022. PMID: 35534898.
33. Akin S, Hosing C, Khouri IF, Ahmed S, Alousi A, Fowler NH, Joseph J, Truxillo J, Ramdial J, Maadani F, Rondon G, Daher M, Im JS, Steiner RE, Westin JR, Iyer SP, Dabaja BS, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
34. Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2021. PMID: 34914826.
35. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
36. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
37. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
38. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
39. Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Nunez Cortes AK, Mendt M, Reyes Silva F, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee PP, Li Y, Li S, Melo Garcia L, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin RE, Shpall EJ, Rezvani K. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep 36(3):109432, 2021. e-Pub 2021. PMID: 34270918.
40. Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
41. Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clin Cancer Res 27(13):3744-3756, 2021. e-Pub 2021. PMID: 33986022.
42. Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol 193(2):216-230, 2021. e-Pub 2021. PMID: 33216984.
43. Laskowski TJ, Daher M, Basar R, Rezvani K. Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. Am Soc Clin Oncol Educ Book 41:1-5, 2021. e-Pub 2021. PMID: 33989022.
44. Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, FLWI L, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2021. PMID: 32902645.
45. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer 9(2), 2021. e-Pub 2021. PMID: 33637601.
46. Mendt M, Daher M, Basar R, Shanley M, Kumar B, Wei Inng FL, Acharya S, Shaim H, Fowlkes N, Tran JP, Gokdemir E, Uprety N, Nunez-Cortes AK, Ensley E, Mai T, Kerbauy LN, Melo-Garcia L, Lin P, Shen Y, Mohanty V, Lu J, Li S, Nandivada V, Wang J, Banerjee P, Reyes-Silva F, Liu E, Ang S, Gilbert A, Li Y, Wan X, Gu J, Zhao M, Baran N, Muniz-Feliciano L, Wilson J, Kaur I, Gagea M, Konopleva M, Marin D, Tang G, Chen K, Champlin R, Rezvani K, Shpall EJ. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol 12:631353, 2021. e-Pub 2021. PMID: 34017325.
47. Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani K. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol 12:626098, 2021. e-Pub 2021. PMID: 33717142.
48. Daher M, Rezvani K. The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective. Semin Hematol 57(4):165-166, 2020. e-Pub 2020. PMID: 33256908.
49. Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Mendt M, Silva FR, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee P, Li Y, Li S, Garcia LM, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin R, Shpall EJ, Rezvani K. Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy. bioRxiv, 2020. e-Pub 2020. PMID: 32995792.
50. Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. e-Pub 2020. PMID: 32717029.
51. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
52. Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
53. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9:2444, 2018. e-Pub 2018. PMID: 30405633.
54. Kondo K, Thompson P, Burger J, Shaim H, Keating M, Estrov Z, Harris D, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through inhibition PD-1/PD- L1 pathway and CLL B10 function. Leukemia, 2017. e-Pub 2017. PMID: 28972595.
55. Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
56. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2017. PMID: 29379494.
57. Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood 128(24):2819-2823, 2016. e-Pub 2016. PMID: 27760759.
58. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
59. Daher M, Lacouture ME, Rathkopf D, Maki RG, Keohan ML, Gansukh B, Chen H, Abou-Alfa GK. Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. J Clin Oncol 29(21):e638-40, 2011. e-Pub 2011. PMID: 21606420.

Invited Articles

1. Biederstädt A, Manzar GS, Daher M. Multiplexed engineering and precision gene editing in cellular immunotherapy. Front Immunol 13:1063303, 2022. e-Pub 2022.
2. Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR-NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov 11(1):45-58, 2021. e-Pub 2021. PMID: 33277313.
3. Basar R, Daher M, Rezvani K. Next generation cell therapies: the emerging role of CAR-NK cells. Hematology Am Soc Hematol Educ Program 2020(1):570-578, 2020. e-Pub 2020. PMID: 33275752.
4. Basar R, Daher M, Rezvani K. Next generation cell therapies: the emerging role of CAR-NK cells. Blood Adv 4(22):5868-5876, 2020. e-Pub 2020. PMID: 33232480.
5. Daher M, Rezvani K. Next generation NK cells for cancer immunotherapy: the promise of genetic engineering. Current Opinion Immunology, 2018. e-Pub 2018. PMID: 29605760.
6. Daher M, Rezvani K. Time for new CAR models: what lies beyond CAR-T cell therapy in the rally against cancer. Cancer Discovery, 2018. e-Pub 2018.

Review Articles

1. Khawaja F, Daher M, Spallone A, Chemaly RF. COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy. Oncology (Williston Park) 37(2):69-77, 2023. e-Pub 2023. PMID: 36862845.
2. Biederstädt, A, Manzar, GS, Daher, M. Multiplexed engineering and precision gene editing in cellular immunotherapy. Frontiers in immunology 13, 2022. e-Pub 2022. PMID: 36483551.
3. Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunology 10(4):e1274, 2021. e-Pub 2021. PMID: 33959279.
4. Pasvolsky O, Daher M, Alatrash G, Marin D, Daver N, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol 11:800110, 2021. e-Pub 2021. PMID: 35083154.
5. Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146-153, 2018. e-Pub 2018. PMID: 29605760.
6. Mehta RS, Randolph B, Daher M, Rezvani K. NK cell therapy for hematologic malignancies. Int J Hematol 107(3):262-270, 2018. e-Pub 2018. PMID: 29383623.

Other Articles

1. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
2. Daher, M, Rezvani, K Exploiting HLA-DR mismatches for CAR therapy in acute myeloid leukemia. Nature Cancer 6(4):561-563, 2025. PMID: 40128568.

Editorials

1. Daher M, Rezvani K. The evolution of NK cell immunotherapy for hematologic malignancies. Seminars in Hematology, 2020.

Abstracts

1. Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Shanley M, Acharya S, Mendt MC, Lin P, Biederstädt A, Rafei H, Banerjee P, Mohanty V, Shaim H, Dede M, Garcia LM, Kerbauy LN, Nunez Cortes AK, Miao Q, Dou J, Reyes FS, Guo X, Kaplan M, Ang S, Jiang XR, Liu E, Liu B, Champlin RE, Kantarjian H, Marin D, Chen K, Abbas HA, Shpall EJ, Rai K, Rezvani K, Daher M, MD. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies. Blood 142(Supplement 1), 2024. e-Pub 2024.
2. Mohanty V, Baran N, Huang Y, Ramage CL, Cooper L, Pelletier SG, He S, Iqbal R, Daher M, Tyner JW, Mills GB, Konopleva M, Chen K. Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs. ASH 2024, 2024. e-Pub 2024.
3. Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, Nunez Cortes AK, Kaplan M, Acharya S, Shaim H, Xu AC, Wu M, Ensley E, Fang D, Banerjee PP, Garcia LM, Tiberti S, Lin P, Rafei H, Munir MN, Moore M, Shanley M, Mendt M, Kerbauy LN, Liu B, Biederstädt A, Gokdemir E, Ghosh S, Kundu K, Reyes-Silva F, Jiang XR, Wan X, Gilbert AL, Dede M, Mohanty V, Dou J, Zhang P, Liu E, Muniz-Feliciano L, Deyter GM, Jain AK, Rodriguez-Sevilla JJ, Colla S, Garcia-Manero G, Shpall EJ, Chen K, Abbas HA, Rai K, Rezvani K, Daher M. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Sci Transl Med 11(16):764, 2024. e-Pub 2024. PMID: 39259809.
4. Tao DL, Abdel-Wahab R, Lin R, Daher M, Liu B, Basar R, Shpall E, Rezvani K, Diab A. Phase I dose escalation and expansion study of PRAME T-cell receptor (TCR) engineered IL15-transduced cord blood–derived natural killer (NK) cells in patients with recurrent and/or refractory melanoma (PRAMETIME-Mel). ASCO Annual Meeting 43(16 Supplement), 2024. e-Pub 2024.
5. Garcia LM, Gangadharan A, Banerjee P, Lin P, Daher M, MD, Rafei H, Kumar B, Rezvani K. Chimeric Antigen Receptor-Engineered NK Cells Overcome CD226 Downregulation As an Immune Escape Mechanism in Acute Myeloid Leukemia. Blood 142(Supplement 1), 2023. e-Pub 2023.
6. Khouri IF, Alzahrani K, Gulbis A, Sasaki K, Jain N, Short NJ, Kadia TM, Daher M, MD, Rafei H, Im JS, Marin D, Olson AL, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Srour SA, Kebriaei P, Shpall EJ, Kantarjian HM, Champlin RE, Jabbour E. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results. Blood 142(Supplement 1), 2023. e-Pub 2023.
7. Lin P, Reyes Silva FC, Lin P, Gilbert AL, Acharya S, Nunez Cortes AK, Banerjee P, Fang D, Garcia LM, Daher M, MD, Basar R, Patel KK, Lee HC, Orlowski RZ, Rafei H, Marin D, Champlin RE, Shpall EJ, Rezvani K. CD70 CAR NK Cells in the Treatment of Multiple Myeloma. Blood 142(Supplement 1), 2023. e-Pub 2023.
8. Acharya S, Basar R, Daher M, MD, Li P, Rafei H, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee P, Garcia LM, Lin P, Mohanty V, Pan Y, Miao Q, Kim KH, Jiang X, Li Y, Liu B, Nunez Cortes AK, Zhang P, Fathi M, Rezvan A, Montalvo MJ, Liu E, Varadarajan N, Chen K, Marin D, Champlin RE, Shpall EJ, Rezvani K. Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies. Blood 142(Supplement 1), 2023. e-Pub 2023.
9. Saliba RM, Marcoux C, Alousi A, Rondon G, Chen J, Daher M, MD, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant. Blood 142(Supplement 1), 2023. e-Pub 2023.
10. Basar R, Daher M, MD, Uprety N, Ensley E, Nunez Cortes AK, Acharya S, Shrestha R, Liu B, Shanley M, Li Y, Reyes FS, Dede M, Rafei H, Shaim H, Kaplan M, Lin P, Banerjee P, Mohanty V, Dou J, Mendt MC, Miao Q, Ammari M, Liu E, Guo X, Kumar B, Biederstädt A, Jiang XR, Ang S, Varadarajan N, Champlin RE, Chen K, Marin D, Shpall EJ, Rezvani K. DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells. Blood 142(Supplement 1), 2023. e-Pub 2023.
11. Rafei H, Basar R, Acharya S, Zhang P, Liu P, Moseley SM, Li P, Daher M, MD, Agarwal N, Marques-Piubelli ML, Uprety N, Garcia LM, Shanley M, Banerjee P, Li Y, Rosemore SL, Kumar B, Nunez Cortes AK, Biederstädt A, Islam S, Kaplan M, Hu B, Manzar G, Lin P, Marin D, Champlin RE, Vega F, Shpall EJ, Rezvani K. Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells. Blood 142(Supplement 1), 2023. e-Pub 2023.
12. Saliba RM, Marcoux C, Alousi A, Rondon G, Chen J, Daher M, MD, Champlin RE, Rezvani K, Shpall EJ, Mehta RS. The Impact of Post-Transplant Cyclophosphamide (PTCy) with or without MMF in the Prevention of De Novo and Progressive / Relapsing Chronic Graft-Versus-Host Disease after HLA-Matched Donor Transplant. Blood 142(Supplement 1), 2023. e-Pub 2023.
13. Ganan-Gomez I, Kumar B, Rodriguez Sevilla JJ, Ma F, Kim YJ, Chien KS, Nelson K, Yang H, Tan R, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Loghavi S, Alatrash G, Bejar R, Rezvani K, Takahashi K, Garcia-Manero G, Daher M, MD, Colla S. Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones. Blood 142(Supplement 1), 2023. e-Pub 2023.
14. Shaim H, Rafei H, Kaplan M, Basar R, Daher M, MD, Shanley M, Banerjee P, Kumar B, Nunez Cortes AK, Islam S, Jiang XR, Kerbauy LN, Lin P, Gokdemir E, Uprety N, Acharya S, Mendt MC, Garcia LM, Biederstädt A, Liu B, Liu E, Ang S, Burger JA, Wierda WG, Ferrajoli A, Shpall EJ, Rezvani K. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis. Blood 142(Supplement 1), 2023. e-Pub 2023.
15. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing C, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. Blood 140(Supplement 1):7502-7503, 2022. e-Pub 2022.
16. Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr 8009, 2022. e-Pub 2022.
17. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 138(Supplement 1), 2021. e-Pub 2021.
18. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood 136(Supplement 1):10-12, 2020. e-Pub 2020.
19. Baran N, Lodi A, Dhungana Y, Sweeney SR, Renu P, Herbrich S, Hoff FW, Skwarska A, Kaplan M, Kuruvilla VM, Cavazos A, Warmoes M, Rojas-Sutterlin S, Haman A, Veiga DT, Furudate K, Ma H, Harutyunyan K, Yang W, Gagea M, Du D, Daher M, Garcia LM, Piya S, Ruvolo V, Shanmugavelandy S, Feng N, Gay JP, Havranek O, Henderson J, Tomczak K, Kaminski M, Herranz D, PharmD, Ferrando A, Jabbour E, Di Francesco ME, Teachey DT, Horton TM, Rezvani K, Yang JJ, Kornblau SM, Davis E, Takahashi K, Andreeff M, Marszalek JR, Lorenzi P, Yu J, Tiziani S, Hoang T, Konopleva M. Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood 136(Supplement 1):18-20, 2020. e-Pub 2020.
20. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma C, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 136(Supplement 1):13-14, 2020. e-Pub 2020.
21. Oran B, Ciurea SO, Mehta RS, Alousi AM, Rondon G, Popat UR, Marin D, Daher M, Im JS, Kebriaei P, Alatrash G, Champlin RE. Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. Blood 136(Supplement 1):20-21, 2020. e-Pub 2020.
22. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood 136(Supplement 1):24-25, 2020. e-Pub 2020.
23. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood 136(Supplememt 1):40-41, 2020. e-Pub 2020.
24. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 136(Supplement 1):24-25, 2020. e-Pub 2020.
25. Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Daher M, Gruschkus SK, Knape C, Whited L, Gulbis A, Marcotulli M, Rondon G, Popat UR, Mehta RS, Konopleva M, Oran B, Ohanian M, Ravandi F, Garcia-Manero G, Alousi AM, Daver N, Champlin RE, Diab A, Alatrash G. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. Blood 136(Supplement 1), 2020. e-Pub 2020.
26. Joseph J, Milton DR, Chen J, Alatrash G, Alousi AM, Bashir Q, Ciurea SO, Daher M, Im JS, Mehta RS, Oran B, Olson AL, Saini N, Srour SA, Andersson B, Champlin RE, Popat UR. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. Journal of Clinical Oncology 38, 2020. e-Pub 2020.
27. Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Mendt MC, Kerbauy L, Shanley M, Nunez Cortez AK, Li L, Banerjee PP, Mohanty V, Lu J, Ozcan G, Ensley E, Nandivada V, Kaplan M, Bdaiwi MH, Ang S, Chen K, Konopleva MY, Champlin RE, Shpall EJ, Rezvani K. Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies. Blood 134(Supplement 1):1936, 2019. e-Pub 2019.
28. Basar R, Daher M, Uprety N, Gokdemir E, Saleh Alsuliman A, Mendt MC, Kerbauy L, Shanley M, Ozcan G, Ensley E, Nunez Cortes AK, Li L, Lu J, Kaplan M, Nandivada V, Bdaiwi M, Li Y, Garcia LM, Liu E, Ang S, Banerjee PP, Champlin RE, Shpall EJ, Rezvani K. Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. Blood 134(Supplement 1), 2019. e-Pub 2019.
29. Basar R, Daher M, Uprety N, Gokdemir ED, Mendt Vilchez MC, Shanley M, Kerbauy LN, Ozcan G, Ensley E, Nunez Cortes AK, Li L, Banerjee PP, Lu J, Kaplan M, Nandivada VD, Bdaiwi MH, Liu E, Ang S, Richard E Champlin RE, Shpall EJ, Rezvani K. Combining CD5-Targeted Chimeric Antigen Receptor Engineering and Genetic Editing of TGF-BR2 for the Treatment of T-Cell Hematologic Malignancies. ASGCT 27(4 supplement 1):39-40, 2019. e-Pub 2019.
30. Daher M, Basar R, Gokdemir ED, Uprety N, Mendt Vilchez MC, Kerbauy LN, Shanley M, Nunez Cortes AK, Li L, Lu J, Kaplan M, Nandivada VD, Bdaiwi MH, Banerjee PP, Liu E, Ang S, Champlin RE, Shpall EJ, Rezvani K. CIS Checkpoint Deletion in Cord Blood Derived iC9/CAR19/IL-15 NK Cells for the Treatment of B-Cell Hematologic Malignancies. ASGCT 27(4 supplement 1):174-175, 2019. e-Pub 2019.
31. Daher M, Cao K, Basar R, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Wang Q, Li L, Rima RM, Pingali Kiran SR, Popat U, Hosing C, Olson AL, Oran B, Mehta SR, Champlin RE, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation. Blood 132(Supplement 1), 2018. e-Pub 2018.
32. Shaim H, Alsuliman A, Gabrusiewicz K, Wei J, Yu J, Basar R, Daher M, Kerbauy L, Mendt M, Muftuoglu M, Li L, Liu E, Imahashi N, Ang S, y G, Banarjee PP, Marin D, Champlin RE, Shpall EJ, Heimberger A, Rezvani K. TGF-β is a key mediator of NK cell dysfunction in gliolastoma. Cancer Research 77(13 Supplement):7445, 2017. e-Pub 2017.
33. Muftuoglu M, Li L, Mak D, Shaim H, Burks JK, Xi Y, Hu B, Shaim H, Imahashi N, Bdiwi, MH, Jimenez J, Banarjee PP, Lim F, Kerbauy L, Kaplan M, DePombo A, Mendt MC, Basar R, Daher M, Marin D, Wang J, Andreeff M, Wierda WG, Jain N, Thompson P, Keating MJ, Armstrong-James D, Champlin RE, Shpall EJ, Rezvani K. Evaluation of T Cell Compartment By Mass Cytometry Reveals Distinct Patterns of Expression of Exhaustion Markers in Chronic Lymphocytic Leukemia. Blood 130(Supplement 1):4283, 2017. e-Pub 2017.
34. Kerbauy LN, Ang S, Liu E, Banerjee P, Wu Y, Shaim H, Wei Inng Lim F, Basar R, Li L, Muftuoglu M, Daher M, Imahashi N, al ME. Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia. Blood 130(Supplement 1):4453, 2017. e-Pub 2017.
35. Li L, Muftuoglu M, Liu E, Ang S, Lv J, Wan X, Cai R, Chen H, Hu B, Jimenez J, Mak D, Burks JK, Bdiwi MH, Banerjee PP, Imahashi N, Kerbauy L, Lu J, Lim F, Mendt M, DePombo A, Daher M, Basar R, Neelapu S, Orlowski RZ, Andreeff M, Marin D, Champlin R, Shpall EJ, Rezvani K. CS1-Specific Chimeric Antigen Receptor Drives Cord Blood NK Cell Maturation and Expansion In Vivo. Blood 130(Supplement 1):4454, 2017. e-Pub 2017.
36. Daher M, Basar R, Shaim H, Gokdemir E, Uprety N, Kontoyiannis A, Mendt MC, Imahashi N, Kerbauy LN, Inng Lim FLW, Li L, Muftuoglu M, Banerjee PP, Champlin RE, Ruvolo PP, Andreeff M, Kantarjian HM, Garcia-Manero G, Shpall EJ, Rezvani K. The TGF-β/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome. Blood 130(Supplement 1):53, 2017. e-Pub 2017.
37. Li L, Muftuoglu M, Chen H, Mak D, Burks JK, Mehta R, Xi Y, Lv J, Hu B, Jimenez J, Kaplan M, Shaim H, Imahashi N, Banerjee PP, Kerbauy L, Mendt M, Lim, F, Daher M, DePombo A, Basar R, Andreeff M, Wang J, Marin D, Champlin R, Shpall EJ, Rezvani K. NK Cell Diversity Influences Outcomes after Cord Blood Transplantation. Blood 130(Supplement 1):1979, 2017. e-Pub 2017.
38. DePombo A, A1 H, Mendt MC, Gi Y, Tong Y, Kaur I, Daher M, Basar R, et al SH. Large-Scale, Bioreactor-Generated Expansion of Umbilical Cord Blood Tissue-Derived Mesenchymal Stromal Cells for Clinical Use. Blood 130(Supplement 1):3198, 2017. e-Pub 2017.
39. Li L, Muftuoglu M, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Daher M, Imahashi N, Vilchez MC, Basar R, Marin D, Champlin RE, Shpall EJ, Rezvani K. Cytomegalovirus Reactivation Shapes NK Cells Diversity Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood 128(22):4588, 2016. e-Pub 2016.
40. Daher M, Marin D, Sobieski C, Shaim H, Basar R, Mendt Vilchez MC, Gokdemir E, Li L, Imahashi N, Muftuoglu M, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani K. KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. Blood 128(22):4330, 2016. e-Pub 2016.
41. Daher M, Hidalgo Lopez J, Randhawa J, Jabbar K, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian H, Cortes J, Hearn K, Reyes S, Bueso-Ramos C, Garcia-Manero G. Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation. Blood 128(22):3191, 2016. e-Pub 2016.
42. Muftuoglu M, Li L, Chen H, Mak D, Gokdemir E, Shaim H, Burks J, Basar R, Imahashi N, Mendt MC, Daher M, Marin D, Wierda WG, Jain N, Keating MJ, Champlin RE, Shpall EJ, Rezvani K. Mass Cytometry Reveals Heterogeneity in the Exhaustion Profile of T-Cells in Chronic Lymphocytic Leukemia and the CD4:CD8 Ratio May be a Reliable Predictor of CD8+ T Cell Compartment "Fitness". Blood 128(22):353, 2016. e-Pub 2016.
43. Kondo K, Burger J, Keating M, Tran J, Muftuoglu M, Daher M, Shpall E, Shaim H, Thompson P, Imahashi N, Alsuliman A, Wierda W, Liu E, Rezvani K. Ibrutinib can modulate the T cell response in chronic lymphocytic leukemia by reducing PD1/PDL1 interactions 126(23), 2015. e-Pub 2015.
44. Daher M, Sobieski C, Marin D, Sekine T, Shpall EJ, Champlin R, Kantarjian H, Garcia- Manero G, Rezvani K. Association between KIR genes and risk of MDS. Journal of Clinical Oncology 33(15 Supplement):7001, 2015. e-Pub 2015.
45. Hausman RE, Chu C, Daher M, Pariser HP. Tissue-specific requirement for cell surface disulfide exchange in embryonic retinal cell adhesion. Investigative Ophtalmology and Visual Science 44(13):1664, 2003. e-Pub 2003.

Book Chapters

1. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
2. Ghanem, S, Abdel Rahman, Z, Khalil, L, Daher, M, Lin, P. Natural Killer Cells, 403-410, 2023.
3. Yepez Guevara, E, Abdel Rahman, Z, Daher, M, Mulanovich, VE. Management of Infections in Stem Cell Transplant Recipients, 429-442, 2023.
4. Rafei, Hind, Basar, Rafet, Rezvani, Katayoun, Daher, May. Chimeric Antigen Receptor-Modified Cells for the Treatment of Solid Tumors: First Steps in a Thousand-Mile March. In: NK Cells in Cancer Immunotherapy: Successes and Challenges. Elsevier/Academic Press, Pages 97-131, 2023.
5. Rafei, H, Basar, R, Rezvani, K, Daher, M. Chimeric antigen receptor-modified cells for the treatment of solid tumors, 97-131, 2022.
6. Guevara Y, Eduardo, Rahman A, Zaid, Daher, May, Mulanovich, Eduardo V. Management of Infections in Stem Cell Transplant Recipients. In: Manual of Stem Cell Transplantation and Cellular Therapies for Hematologic Malignancies. Elsevier Books, 2022.
7. Ghanem S, Abdel Rahman Z, Lin P, Daher M. Natural Killer Cells: A Promising Cellular Therapy Platform to Conquer Cancer. In: Manual of Hematopoietic Stem Cell Transplantation and Cellular Therapies. Elsevier Books, 2022.

Letters to the Editor

1. Saliba, RM, Lee, SJ, Carpenter, P, Hill, GR, Lee, CJ, Alousi, AM, Daher, M, Chen, GL, Champlin, RE, Rezvani, K, Shpall, E, Mehta, RS. Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus-seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica 109: 2321-2325, 2024.
2. Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.